Thomas Jensen
Founder at ALLARITY THERAPEUTICS, INC.
Net worth: 32 $ as of 30/03/2024
Profile
Thomas H.
Jensen is the founder of Medical Prognosis Institute A (founded in 2006), XRGenomics Ltd.
(founded in 2012), Allarity Therapeutics A (founded in 2004), and Allarity Therapeutics, Inc. (founded in 2020).
At Allarity Therapeutics A and Allarity Therapeutics, Inc., he holds the title of Chief Executive Officer & Director.
Mr. Jensen's former job was as the Chief Technology Officer at Oncology Venture Sweden AB.
He obtained his undergraduate degree from the Technical University of Denmark.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
20/02/2024 | 106 ( 0.00% ) | 32 $ | 30/03/2024 |
Thomas Jensen active positions
Companies | Position | Start |
---|---|---|
ALLARITY THERAPEUTICS, INC. | Founder | 05/04/2021 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Founder | 31/12/2003 |
Former positions of Thomas Jensen
Companies | Position | End |
---|---|---|
Medical Prognosis Institute A/S
Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Founder | - |
XRGenomics Ltd. | Founder | - |
Oncology Venture Sweden AB
Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Chief Tech/Sci/R&D Officer | - |
Training of Thomas Jensen
Technical University of Denmark | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ALLARITY THERAPEUTICS, INC. | Health Technology |
Private companies | 4 |
---|---|
Medical Prognosis Institute A/S
Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Health Technology |
Oncology Venture Sweden AB
Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Health Technology |
XRGenomics Ltd. | |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
- Stock Market
- Insiders
- Thomas Jensen